Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Reduction in Invasive Pneumococcal Disease Following Implementation of the Conjugate Vaccine in the Oxfordshire Region, England.

08:19 EDT 24th July 2014 | BioPortfolio

Summary of "Reduction in Invasive Pneumococcal Disease Following Implementation of the Conjugate Vaccine in the Oxfordshire Region, England."

Pneumococcal conjugate vaccine to 7 capsular types has been highly effective in the US since its introduction in 2000. The same vaccine was adopted by the UK in 2006. Ongoing surveillance since 1995 of invasive pneumococcal disease in Oxfordshire, UK, allowed assessment of the impact of vaccine intervention. The vaccine significantly reduced invasive pneumococcal disease among the target group, children less than 2 years; incidence rate ratio (IRR)=0.62 [95%CI 0.43-0.90] (p=0.008) comparing the 3 years pre- and post-implementation with a residual incidence of 22.4/100,000 children. The reduction was even greater when comparing 11 years pre with the 3 years post implementation of vaccine; IRR=0.53 [0.39- 0.70] p<0.0001. There was a marked direct effect of the vaccine evidenced by substantial reductions in the 7 serotypes contained in the vaccine. There was also a clear reduction in invasive pneumococcal disease for those serotypes contained in the vaccine among those older than 2 years when comparing both the 3 and 11 year pre PCV7 time periods with IRR=0.57 [0.47-0.69] p<0.0001 and IRR=0.50 [0.43-0.58] p<0.0001 respectively, indicating a strong herd effect. There was a significant, though moderate, rise in the serotypes not contained in the vaccine, with clear evidence for replacement in some serotypes.

Affiliation

1 University of Oxford;

Journal Details

This article was published in the following journal.

Name: Journal of medical microbiology
ISSN: 1473-5644
Pages:

Links

PubMed Articles [24692 Associated PubMed Articles listed on BioPortfolio]

Reduction of invasive pneumococcal disease three years after the introduction of the 13 valent conjugate vaccine in the Oxfordshire region, England.

Background. The 7-valent pneumococcal conjugate (PCV7) vaccine's impact on invasive pneumococcal disease (IPD) is well described, but few reports exist on the additional impact of the 13-valent vacc...

Clinical features and outcomes of serotype 19A invasive pneumococcal disease in Calgary, Alberta.

The recent introduction of the seven-valent pneumococcal conjugate vaccine has led to changes in the proportion of disease caused by different serotypes. The serotypes targeted by the vaccine have bee...

Streptococcus pneumoniae Carriage Prevalence in Nepal: Evaluation of a Method for Delayed Transport of Samples from Remote Regions and Implications for Vaccine Implementation.

Pneumococcal disease is a significant cause of morbidity and mortality in young children in Nepal, and currently available pneumococcal conjugate vaccines offer moderate coverage of invasive disease i...

Socioeconomic and Racial Disparities of Pediatric Invasive Pneumococcal Disease After the Introduction of the 7-valent Pneumococcal Conjugate Vaccine.

Racial differences have been well described for invasive pneumococcal disease (IPD), but little information exists on how race interacts with community socioeconomic factors.

Trends of Pneumococcal Meningitis in Children after Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in France.

Streptococcus pneumoniae remains an important cause of bacterial meningitis in children younger than 2 years. Here we analyzed data from an active surveillance network established 12 years ago by the...

Clinical Trials [5521 Associated Clinical Trials listed on BioPortfolio]

Study Evaluating Immune Response of Children Revaccinated With Pneumococcal Conjugate Vaccine

The primary purpose of this study is to characterize the immune response to a single dose of 13-valent pneumococcal conjugate vaccine (13vPnC) in children previously vaccinated with a prim...

Effect of Two Versus Three Pneumococcal Conjugate Vaccinations

Two( 2) or three (3) instead of four vaccinations before the age of 6 months with pneumococcal conjugate vaccine are presumed to protect children against invasive pneumococcal disease like...

Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine Administered to Infants in Korea

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC), relative to a 7-valent pneumococcal conjugate va...

A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

To assess whether HIV-infected infants who receive a heptavalent pneumococcal conjugate vaccine have more local reactions at the site of injection and systemic reactions than placebo subje...

Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomita...

Medical and Biotech [MESH] Definitions

A combined vaccine used to prevent infection with diphtheria and tetanus toxoid. This is used in place of DTP vaccine (DIPHTHERIA-TETANUS-PERTUSSIS VACCINE) when PERTUSSIS VACCINE is contraindicated.

A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)

A febrile disease caused by STREPTOCOCCUS PNEUMONIAE.

An attenuated vaccine used to prevent and/or treat HERPES ZOSTER, a disease caused by HUMAN HERPESVIRUS 3.

A bacterial vaccine for the prevention of brucellosis in man and animal. Brucella abortus vaccine is used for the immunization of cattle, sheep, and goats.

Search BioPortfolio: